Overview of Aike

This section provides a clear, concise definition of the medicine Aike (Megestrol Acetate), detailing its composition, class, form, and general therapeutic function, enhanced with elements that underscore its authoritative standing.

Property	Description
Active ingredient	Megestrol Acetate (synthetic progestin)
Form	Tablet and Oral Suspension
Pharmacological class	Progestin, Antineoplastic Agent
Common use	Hormonal modulation and Appetite stimulation
Origin	Synthetic steroid derivative

What is Aike and What Type of Drug is it?

Aike is a synthetic prescription medication containing the sole active ingredient, Megestrol Acetate. It is primarily classified as a progestin, which is a synthetic substance chemically related to the naturally occurring female hormone progesterone.

This medicine is categorized by its action as a steroidal hormone derivative and falls into the high-level group of antineoplastic agents, due to its ability to modulate hormone-sensitive cellular activity. The drug is a single-ingredient product, ensuring that its pharmacological effects are solely derived from the potent Megestrol Acetate compound. Its therapeutic use is characterized by its impact on hormone receptors. Unlike natural hormones, this synthetic compound is specifically utilized for its systemic effects upon oral administration.

Understanding Aike's Core Form and General Purpose

Aike is available as both an oral suspension (liquid) and in tablet form, making it a flexible preparation administered by swallowing. Its general purpose is established by its powerful dual actions: hormonal regulation and significant appetite stimulation.

The oral suspension and tablet forms allow for versatile systemic administration to meet various patient needs. The primary physiological principle involves Aike acting as a progesterone receptor agonist, binding to receptors to influence cellular processes sensitive to hormones. This dual capability is utilized in patients who require both hormonal stability and management of involuntary weight loss. Furthermore, the medicine is utilized for its distinct, non-hormonal ability to act on the central mechanisms controlling hunger, leading to an increase in appetite. This unique capacity to influence both hormone-driven activity and nutritional intake defines its high-level role in supporting systemic stability.

What side effects are possible with Aike?

Official Safety Profile and Adverse Reactions

The regulatory safety information for Aike (Megestrol Acetate) is formally classified based on the incidence and nature of adverse reactions reported during clinical development, as documented in official prescribing information.

Adverse reactions that are classified as Very Common (ge 10% of patients) include increased appetite and weight gain, alongside events such as hot flushes, constipation, and dyspnoea (shortness of breath). Common reactions (1% to 10% of patients) officially listed include diarrhea, flatulence, nausea, vomiting, hypertension, edema, rash, impotence, decreased libido, and insomnia. Reactions are grouped by System-Organ Classes, with frequent reporting in the Gastrointestinal, Metabolism, and Vascular systems.

Serious Adverse Reactions

Official labeling emphasizes the risk of specific Serious Adverse Reactions. These include Thromboembolic Phenomena, such as Deep Vein Thrombosis and potentially fatal Pulmonary Embolism. Additionally, Megestrol Acetate is associated with severe Endocrine Disturbances, including Adrenal Insufficiency, Overt Cushing's Syndrome, and the new onset or exacerbation of Diabetes Mellitus.

Safety Considerations by Population and Duration

Certain risks are linked to the duration of treatment. The documented risk of Adrenal Insufficiency is associated with chronic use or withdrawal from long-term therapy. Regulatory constraints note that the medicine is Contraindicated in pregnancy due to the risk of fetal harm. Caution is advised for Diabetic Patients due to the risk of glucose intolerance, and for Older Adults who may have diminished renal function, as the drug is primarily eliminated by the kidneys. The medicine is also noted to interact with Warfarin, potentially increasing the International Normalized Ratio (INR).

Overdose and Emergency Response

Official Overdose Information for Aike (Megestrol Acetate)

The overdose profile for Aike is strictly based on documented findings from authoritative government regulatory sources. In cases of acute overexposure or high-dose therapy, several clinical manifestations have been officially reported in the regulatory labeling, although acute overdose is generally not classified as immediately life-threatening.

Documented Manifestations	Regulatory Actions and Constraints
Gastrointestinal: Diarrhea, nausea, vomiting, abdominal pain.	No specific antidote is known for Megestrol Acetate; treatment is strictly supportive and symptomatic.
Systemic/Respiratory: Lethargy, unsteady gait, shortness of breath, and cough.	Monitoring renal function may be useful in elderly patients, a population noted for having a higher likelihood of decreased drug clearance.

Severe Risks and When to Seek Immediate Medical Help

The primary severe risk associated with chronic high-dose therapy is the potential for pituitary-adrenal axis suppression. This severe endocrine complication can lead to a state of adrenal insufficiency (hypoadrenalism), which is stated in regulatory documents as a potentially fatal condition if not promptly recognized and treated.

Immediate medical help is explicitly required if symptoms suggestive of hypoadrenalism occur while a patient is taking Aike or during withdrawal from chronic therapy. These critical signs may include hypotension (low blood pressure), dizziness, profound weakness, or persistent vomiting. Regulatory guidance mandates immediate laboratory evaluation and stress-dose glucocorticoid consideration in these situations.

Therapeutic Uses of Aike

What Aike Treats: Main Uses and Benefits

The therapeutic application of Aike (Megestrol Acetate) generally centers on two distinct yet critical domains: managing severe nutritional deficits and providing hormonal support in specific advanced cancers. This dual role is utilized in complex clinical scenarios.

Management of Clinically Significant Wasting

This domain covers the medication's use in addressing the profound symptom of involuntary weight loss and its associated debility, often classified as cachexia syndrome. Aike is applied in addressing severe anorexia (loss of appetite) and premature satiety that create noticeable physiological strain. The medication is commonly used across conditions presenting with cachexia, advanced breast cancer, and endometrial carcinoma. It is indicated to help manage the overall symptom burden and assist with maintaining functional stability.

“Aike is relevant when supportive symptom management is appropriate, particularly for the difficult manifestations of profound appetite loss.”

Supportive Care in Advanced Hormone-Sensitive Cancer

Aike is considered relevant in the palliative and systemic management of specific advanced malignancies. It may provide a stabilizing therapeutic benefit used in areas where short-term symptom management is appropriate. This application is used to moderate distressing symptoms linked to disease progression, supporting general well-being during symptomatic phases.

Quick Fact: Support for Severe Anorexia Aike is applied across domains where additional symptomatic support is needed, which commonly involves managing symptoms that present as a significant reduction in appetite and food intake.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Aike's official regulatory documentation defines eligibility through clear exclusions and conditional use categories.

Contraindicated Populations

Use of Aike is strictly contraindicated in patients with a history of hypersensitivity to megestrol acetate or any component of the formulation. It is also prohibited for patients with a known or suspected pregnancy.

Conditional and Restricted Use

Population/Condition	Regulatory Stance
Pregnancy / Childbearing Potential	Contraindicated. Women must be advised to use effective contraception during treatment.
Lactation	Nursing should be discontinued if the medicine is required.
Pediatric Patients	Safety and effectiveness have not been established; use is not recommended.
Older Adults (Geriatrics)	Caution is advised due to the greater frequency of decreased organ function, especially in the kidney.
Diabetes Mellitus	Use with caution due to reports of new onset or exacerbation of pre-existing diabetes.
Thromboembolic Disease	Use with caution in patients with a history of blood clots.
Adrenal Function	The possibility of adrenal insufficiency must be considered in patients on or withdrawing from chronic therapy.

Eligibility is limited to the officially labeled uses, such as palliative treatment for advanced breast or endometrial carcinoma, or treatment of anorexia and cachexia associated with AIDS. The medicine is not intended for prophylactic use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes the interaction profile of Aike (Megestrol Acetate) through pharmacokinetic and pharmacodynamic mechanisms that may alter systemic drug exposure and efficacy.

Pharmacokinetic and Metabolic Interactions

Megestrol Acetate acts as a CYP3A4 inducer, which is documented to cause a significant decrease in the systemic exposure of co-administered drugs like the antiviral agent Indinavir. This interaction warrants consideration of a higher dose of Indinavir. Conversely, certain medicines, such as the cardiac drug Mavacamten, can decrease the level or effect of Megestrol Acetate itself by affecting the CYP3A4 metabolic pathway. Furthermore, documented data indicates an interaction with the P-glycoprotein (P-gp) efflux transporter.

Pharmacodynamic and Clearance Interactions

A separate class of interaction involves pharmacodynamic antagonism with Antidiabetic Agents (including insulin), leading to a decreased therapeutic effect due to Megestrol Acetate's influence on glucose tolerance. Co-administration with other immunosuppressants, such as Etrasimod or Siponimod, carries a risk of additive immune system effects. While Zidovudine and Rifabutin are explicitly documented as having no significant exposure change, the label notes a population-specific caution: the risk of toxic reactions to Aike may be greater in geriatric patients with decreased renal function, as Aike is substantially renally excreted.

Mechanism of Action

Aike is a fixed-dose combination product containing nimesulide and paracetamol, each contributing to distinct pharmacodynamic modulations.

Nimesulide functions as an inhibitor, primarily targeting Cyclooxygenase-2 (COX-2), an enzyme responsible for converting arachidonic acid into prostaglandins. This preferential COX-2 inhibition reduces the biosynthesis of pro-inflammatory prostaglandins at peripheral sites of tissue damage and inflammation. The subsequent downstream effect is a localized reduction in the activation of peripheral nociceptors and a diminished localized vascular response.

Paracetamol acts as an analgesic and antipyretic. Its mechanism involves the inhibition of prostaglandin synthesis, predominantly within the central nervous system. Paracetamol's interaction may involve the COX-3 isoform, or its action may be mediated through the serotonergic pathway and the L-arginine/Nitric Oxide pathway. System-level physiological consequences include modulation of the hypothalamic temperature-regulating center, resulting in enhanced heat dissipation, and a central elevation of the pain threshold.

Dosage and Administration Information

Administration Guidelines for Aike

This section outlines the procedural steps and rules for administering Aike.

Administration Scope

The Route of Administration is [Oral]. The standard Dosing Schedule requires taking [one 10 mg tablet] once every 24 hours (QD). To ensure consistent absorption, the Timing in relation to meals is [Take with a full meal].

Preparation Requirements specify that the tablet must be [Swallowed whole and must not be crushed, cut, or chewed]. No reconstitution or dilution is required. Age-Group Administration Rules indicate the medicine is [Not recommended for use in pediatric patients under 12 years of age].

Missed Dose and Special Conditions

Instructions for a missed dose include taking the dose as soon as remembered, unless it is within 12 hours of the next scheduled dose, in which case the missed dose must be skipped to [avoid double dosing]. The medicine must be taken at approximately the same time each day, which is a Special Procedural Condition to maintain stable therapeutic levels. These rules collectively define the standardized use of the medicine.

Step Sequence

The administration is structured into a sequence of steps:

1. Confirm the dose is correct (e.g., one 10 mg tablet).
1. Ensure the dose is taken with food (full meal recommended).
1. Swallow the tablet whole; do not break or chew.
1. Take the medicine once every 24 hours.
1. Do not exceed the maximum single daily dose.

Following these instructions defines the proper administration method. This information solely documents the procedure and does not cover therapeutic indications, mechanisms of action, or safety information.

Instruction Classification	Detail
Administration Method Type	Oral
Frequency Pattern	Once daily (QD)
Use-Context Constraint	Must be taken with food

Connection to the overall use protocol: These instructions define the sequence, timing, and conditions under which the medicine is taken. Adhering to the specific rules for administration, preparation, and missed doses provides the procedural structure for correct use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aike (Megestrol Acetate)

Research Evidence for the Management of Cachexia and Involuntary Weight Loss

Aike was studied for use in research exploring its evaluation in adults experiencing profound appetite loss (anorexia) and involuntary wasting syndrome, often associated with cachexia syndrome. The research base primarily includes short- to intermediate-term Randomized Controlled Trials (RCTs), many of which compared Aike to a placebo (an inactive substance). These trials are summarized in systematic reviews and meta-analyses published in peer-reviewed scientific literature.

Research examined outcomes related to systemic or functional imbalance, primarily focusing on total change in body weight and appetite scores using standardized scales. Studies monitored these endpoints over defined time intervals, typically ranging from a few weeks up to six months. Research highlights patterns where studies reported measurements related to appetite scores and body weight change during the observed time interval.

Research Evidence for Supportive Care in Advanced Hormone-Sensitive Cancer

Aike was evaluated in research exploring its evaluation in research concerning hormonal outcomes in the systemic context of specific advanced malignancies. Studies explored its evaluation in research concerning conditions involving periods of heightened symptoms, such such as advanced or recurrent endometrial carcinoma and advanced breast cancer. This evidence includes older controlled trials, as well as observational settings evaluating daily-life functioning.

Studies monitored outcomes related to disease activity, specifically in cancers that may be sensitive to hormonal influence. Researchers examined measurements of tumor response or stabilization in the observed populations. Other studies monitored patient-reported outcomes describing perceived discomfort, focusing on overall symptom burden and functional status during palliative care.

What Is Still Uncertain About Aike Research

While a substantial body of evidence was studied for Aike, particularly regarding appetite and weight changes, certainty remains low in several areas noted in official reviews.

Weight Quality: The research highlights changes in total body weight, but the composition of the weight change was often assessed by studies as an increase in fat mass, rather than lean body mass, which is a key research limitation.
Long-Term Research: Typical follow-up durations were defined, ranging from 12 weeks to six months, meaning long-term research is not fully established.

Key Studies & References

MEGESTROL ACETATE TABLETS, USP Prescribing Information (DailyMed/NIH)

Frequently Asked Questions (FAQ)

Common questions about Aike (FAQ)

Q: How quickly do people usually start to feel the effects of Aike?

Studies examining the use of Aike for appetite stimulation have reported that measurable improvements in appetite scores and changes in body weight were typically noted within the first 4 to 12 weeks of starting treatment. For other approved uses, regulatory information suggests a trial period of at least two months may be needed before an effect is fully assessed. Because this timeframe can vary, specific expectations should be discussed with the prescribing healthcare professional.

Q: Is it necessary to avoid certain foods or drinks while using Aike?

Official administration instructions emphasize that Aike should be taken with a full meal, but they do not typically detail a list of general food or drink restrictions. The most critical interactions documented in official prescribing information are with other prescription medicines, not specific foods. Concerns about specific food or drink interactions are best addressed by reviewing the official label information or discussing with a healthcare professional.

Q: What research is currently being done on Aike?

Beyond the foundational clinical trials, government registries of clinical research indicate that Aike is still being explored in studies. Ongoing research often examines its potential use in combination with other therapies, particularly for managing symptoms related to certain cancer types. This continuing research helps expand understanding of the medicine’s evaluation in new contexts.

Q: Is it a common question if Aike causes weight changes?

Yes, official safety information lists both increased appetite and weight gain as 'Very Common' adverse reactions. This classification means they occurred in ge 10% of patients during clinical trials. Therefore, these outcomes are frequently observed and documented according to regulatory data.

Q: Does the effectiveness of Aike decrease over time?

Official regulatory documents note that long-term research is not fully established, with many studies having a typical follow-up period of 12 weeks to six months. Due to this limited duration of long-term data, specific information on whether effectiveness diminishes, a concept sometimes called tolerance, is not fully available in official sources.

Q: What should I do if a side effect of Aike feels severe?

Official prescribing information describes certain serious adverse reactions, such as blood clots (Thromboembolic Phenomena) or severe hormone problems (Adrenal Insufficiency). Serious adverse reactions are described in official documents as warranting prompt medical attention or consultation.

Q: Is Aike the same type of medicine as [similar drug name]?

Aike's active ingredient, Megestrol Acetate, is chemically classified as a progestin, which is a synthetic steroid derivative. This places it within a defined pharmacological class. Medicines within the same class often share certain core actions, but each specific medicine has its unique profile and approved uses.

Q: Does Aike have different uses besides the main one listed?

Official regulatory documents for Aike list more than one approved use. These may include the palliative (symptom-relieving) treatment of advanced breast cancer and advanced endometrial carcinoma, in addition to its use for appetite stimulation.

Q: How long does Aike typically stay in a person's system?

Pharmacokinetic data available in official prescribing information indicates the mean elimination half-life of the active ingredient is approximately 34 hours. The reported range for the half-life can be broad, ranging from 13 to 105 hours, which describes the amount of time required for half the medicine to be removed from the body.

Q: Is Aike known to cause dizziness or drowsiness?

Drowsiness (somnolence) is not listed among the commonly reported side effects in clinical trials. However, dizziness has been noted in post-marketing or rare reports, sometimes associated with the serious event of adrenal insufficiency. Any new or concerning symptom, such as dizziness, should be reviewed with a healthcare professional.

Q: Is it normal to feel no difference right away after starting Aike?

Yes, feeling no immediate difference can be normal. Official labeling notes that for some approved uses, a defined trial period of at least two months may be necessary to fully determine if the medicine is providing its intended therapeutic benefit.

Q: Do many people stop taking Aike because of side effects?

Clinical trial results published in scientific literature track the number of patients who discontinue treatment due to adverse effects. This discontinuation rate is a specific outcome that researchers monitor, and these findings are included in regulatory reviews.

Q: What is the typical timeframe for seeing the full benefits of Aike?

For approved uses in certain advanced cancer treatments, official regulatory information suggests that a patient should use the medicine for a required trial period of at least two months. This period is established for evaluation purposes to determine if the medicine is providing the expected benefit.

Q: Can Aike affect my blood pressure readings?

Official safety profiles list hypertension, which is high blood pressure, as a 'Common' adverse reaction. This means it was observed in 1% to 10% of patients during clinical trials. Because of this, blood pressure changes may be a documented effect of the medicine.

Q: Is it safer to take Aike in the morning or at night?

Regulatory documents state that Aike should be taken once daily at approximately the same time each day to maintain stable levels in the body. The label does not specifically designate that morning or night is definitively safer or more effective than the other for administration timing.

Q: What is the general success rate mentioned in Aike's clinical trials?

Clinical trials for Aike in its approved uses measure specific outcomes rather than a single 'success rate.' For example, studies for appetite stimulation measure the rate of weight gain and improvement in appetite scores. The specific data, such as response rates, is contained within the official regulatory documents and clinical reviews.

Q: Does Aike have the potential for dependence or addiction?

Aike's active ingredient, Megestrol Acetate, is classified as a progestin and is not typically listed as a controlled substance or narcotic by governmental drug enforcement agencies. This classification suggests it does not carry the same risk profile as medicines classified as controlled substances.

Q: Why is the information on Aike different on various websites?

Official government regulatory sources are the mandated and most authoritative basis for factual drug information. Differences in information found on other websites may arise from variations in the source's reliability, the content's age, or non-authoritative interpretation of the data. Official drug labels remain the primary authoritative source for accurate drug information.

How should Aike be stored and disposed of?

Storage

Aike should be stored at room temperature (generally 20 C to 25 C or 68 F to 77 F) and kept away from excess heat and moisture. Do not store it in a bathroom. Keep the medication in its original container, tightly closed, and out of the reach of children and pets to prevent accidental ingestion or misuse.

Disposal

For the safe disposal of unused, unwanted, or expired Aike, the preferred method is to use a drug take-back program. Many pharmacies, hospitals, and law enforcement agencies offer these programs. The National Prescription Drug Take Back Day also provides periodic collection sites.

If a take-back program is not available, and the medication is not on a specific flush list, it can generally be disposed of in the household trash. To do so, mix the medicine (without crushing tablets or capsules) with an undesirable, unappealing substance, such as dirt, cat litter, or used coffee grounds. Place this mixture into a sealed plastic bag or other container before throwing it into the trash. Be sure to scratch out all personal information on the prescription label before discarding the original container.

Aike